October 17, 2017 10:05 AM EDT
Financing
Startups

Pfiz­er, NEA back Cy­dan II's plans to launch a fresh slate of biotech star­tups fo­cused on rare ge­net­ic dis­eases

John Carroll

Editor & Founder

Six months ago the biotech start­up Vtesse grabbed a $200 mil­lion up­front pay­out for their buy­out deal with Su­cam­po, pro­vid­ing a nice en­dorse­ment for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times